Shares of major vaccine manufacturers Moderna and BioNTech fell despite receiving positive ratings from Wolfe Research, highlighting broader market volatility in the biotech sector.

BioNTech shares climb alongside a broader post-pandemic rebound in the biotechnology sector, though analysts caution that stronger underlying fundamentals are needed to sustain long-term growth.

An analysis compares Pfizer Inc. (PFE) and BioNTech SE (BNTX) to determine which pharmaceutical giant is better positioned for the market and healthcare landscape in the post-COVID era.

BioNTech has adjusted its financial forecast as new CEO Guido Oelkers takes the helm, with the company now prioritizing the success of two cancer medications to offset declining revenues from its vaccine business.

Pfizer and BioNTech are facing global patent lawsuits from Arbutus and Roivant Sciences concerning the technology used in their COVID-19 vaccines.

US pharmaceutical company Moderna is looking to invest in Germany and has shown interest in acquiring facilities belonging to its former competitor, BioNTech, while also calling for improved conditions for pharmaceutical companies.

An article evaluates whether BioNTech SE (BNTX) is a good stock investment opportunity at the current time.

The German state of Hessen is expressing its commitment to ensuring that Biontech's operations remain in Marburg. This news comes from a liveblog covering current events in Frankfurt and Hessen.

BioNTech, the company behind a major COVID-19 vaccine, is reportedly facing an 'end of an era' as it navigates economic challenges, cuts, and closures after its pandemic-era billions. The company is now placing a significant bet on its cancer research.

Despite the ongoing conflict in Iran, German industry has reported a surprising increase in new orders, indicating resilience in the business sector.

The Mayor of Marburg has strongly criticized the planned closure of the Biontech plant in Lahn, stating that the company's profits were financed by tax money.

A German government spokesperson confirmed that the country's vaccine supply remains secure, as losses in BioNTech's domestic production can be offset by other companies.

BioNTech's announced closure of its production facilities in Germany is drawing sharp criticism from figures like the CureVac founder and unions, with warnings of potential supply shortages.

BioNTech announced plans to close several locations and eliminate up to 1,860 jobs as part of a restructuring effort.

The city of Mainz, known for Biontech, is reportedly considering implementing a tourist accommodation tax as its 'golden times' are over, indicating financial difficulties.

German biotechnology company BioNTech plans to close its vaccine manufacturing plant in Singapore by 2027, affecting 85 employees.

The founding couple of Biontech is stepping down from operational roles, prompting the company to search for a new CEO, primarily in the United States. The largest shareholder defends the move, while Mainz hopes not to lose a valuable asset.

A BioNTech executive sold shares worth seven million dollars just one day after the company's founders announced their withdrawal from leadership, with the timing described as unfortunate despite the sale being pre-registered.

The co-founders of BioNTech have announced their departure from the company to establish a new venture focused on mRNA technology.

Ugur Sahin and Özlem Türeci, the founders of BioNTech, are reportedly stepping back from the company's operational management, a move described as a potentially strategic decision by the research couple.

BioNTech shares declined following news that its cofounders plan to exit the company and after its financial outlook missed forecasts, causing the shares to fall.

These are the stocks posting the largest moves in early trading.

BioNTech SE (BNTX) is experiencing a rally in its stock due to a solid oncology strategy.

Pharmaceutical stocks Moderna and BioNTech have seen significant price increases as investors reassess the commercial viability and pipeline strength of messenger RNA therapies beyond vaccines.

BioNTech's stock experienced a significant 22% surge after positive news regarding Moderna's cancer vaccine, though the article questions the sustainability of these gains.

A study by IIT Kharagpur reveals that Kolkata's rapid concrete development has led to increased city temperatures, prompting a call for the city to reconsider its growth strategies. Separately, a trade union is demanding the sale of a BioNTech production site in Marburg.

In an interview, Nobel Prize winner Katalin Karikó stated that the Biontech vaccine might not exist if she hadn't been dismissed from her university at age 58, highlighting her journey to laying the groundwork for the COVID-19 vaccine.

Cathie Wood's Ark Invest has sold $7.4 million worth of BioNTech stock. This move comes as Ark Invest continues to adjust its biotech holdings.

Moderna is reportedly considering German production sites, potentially in response to BioNTech's plant closures, indicating a strategic move in its manufacturing capabilities.

BioNTech (BNTX) and Bristol Myers have shared new results from their ROSETTA Lung-02 study, providing updates on their collaborative research.

Biontech CEO Uğur Şahin addressed shareholders regarding upcoming job cuts, but investors appear more concerned about the departure of the founding couple.

A report on how BioNTech, the German pharmaceutical company that developed the first approved mRNA COVID-19 vaccine, has seen its fortunes decline six years after its pandemic peak.

BioNTech, once celebrated for its COVID-19 vaccines, is facing challenges including falling demand, restructuring, and the departure of its founders, as it shifts focus to ambitious cancer trials.

BioNTech has announced layoffs as the company faces a significant decline in revenue from its COVID-19 vaccines.

An expert advises the German federal government to assess vaccine capacities for potential crises, following BioNTech's withdrawal from Germany, with allegations of deception also surfacing from the acquired company Curevac.

Gewinn von BMW bricht ein +++ Samsung erreicht Börsenwert von einer Billion US-Dollar +++ US-Handelsdefizit steigt auf 60 Milliarden Dollar +++ Biontech schließt Standorte und streicht bis zu 1860…

BioNTech has outlined plans for a share buyback program of up to $1 billion and aims for approximately €500 million in annual savings. The company also reaffirmed its 2026 revenue target of €2.0B-€2.3B.

BioNTech's stock price target has been increased following the successful release of T-Pam data, indicating positive developments for the biotechnology company.

Pfizer and BioNTech have halted a U.S. COVID-19 vaccine study, citing difficulties in recruitment and weak demand for the shots.

The German scientist speaks with 'La Vanguardia' about the potential of mRNA against cancer, her decision to leave BioNTech, and the value of diversity in laboratories.

With their Covid vaccines, Ugur Sahin and Özlem Türeci became world-famous overnight. Now the doctor couple prefers to research again instead of managing.

Uğur Şahin és Özlem Türeci új mRNS-startupot alapítanak.

BioNTech's shares declined following news that its cofounders plan to exit the company and after its financial outlook missed forecasts, causing the shares to fall.

BioNTech shares fell after its co-founders announced plans to exit and the company's financial outlook missed forecasts.

Ugur Sahin e Oezlem Tuereci terão até ao final deste ano uma nova empresa dedicada a fazer avançar os medicamentos da próxima geração com ARN-mensageiro.

Moderna is facing a lawsuit alleging that its COVID-19 vaccine violates a patent linked to the Pfizer/BioNTech shot.

Moderna's stock fell by 7% as traders booked profits following a significant year-to-date surge, with BioNTech and Merck also experiencing declines. In contrast, Tracsis stock saw a notable surge in its value.

Leerink analysts suggest that BioNTech's recent stock rally, spurred by a Moderna trial win, is likely to be short-lived.

BioNTech projects revenues between €1.6 billion and €1.9 billion by 2026, as the company continues to advance its oncology catalysts into late-stage development by the same year.

Shell verkauft europäisches Onshore-Geschäft an Totalenergies +++ Astrazeneca prüft offenbar Fusion mit Bristol Myers +++ Fielmann dämpft Erwartungen an Smartglasses +++ Neuigkeiten im…

BioNTech has reportedly initiated contact with potential buyers regarding its plans to exit several German sites.

Poland has received a demand from Belgium for nearly 170 million PLN (approximately €37 million) in registration tax related to an ongoing court case between Poland and Pfizer BioNTech concerning unused and unpaid vaccine doses.

The German trade union IG BCE has criticized Biontech for a lack of transparency regarding its planned sale of several plants, raising concerns about job security and the future of many employees.

During its Annual General Meeting, BioNTech outlined plans for an oncology push, approved a $1 billion share buyback program, and announced manufacturing cuts.

German biotechnology company BioNTech, renowned for developing the first approved COVID-19 vaccine, is experiencing significant financial difficulties as its vaccine revenues have dried up, impacting its cancer drug development efforts.

BioNTech, the German biotechnology company, is experiencing a significant downturn, marked by the withdrawal of its founders and the closure of factories. This comes after a period of rapid growth, bringing the company "back to reality."

The founder of biotechnology company Curevac has publicly accused rival firm Biontech of deception. The specific nature of the alleged deception was not detailed in the provided titles.

A business news ticker reports that Daimler Truck's profit has fallen by 80 percent, Samsung's market value reached one trillion US dollars, the US trade deficit increased, and Biontech is cutting up to 1860 jobs.

BioNTech has announced plans to close several sites in Germany and Singapore, a move that will impact approximately 1,860 employees.

Morgan Stanley has slightly raised its price target for BioNTech SE (BNTX) as it updates its biopharma coverage models.

A new antibody-drug conjugate, Trastuzumab Pamirtecan, developed by BioNTech and DualityBio, has demonstrated clinically meaningful efficacy in patients with HER2-expressing, recurrent endometrial cancer. The findings suggest a promising new treatment option for this patient group.

BMO Capital has reduced its price target for BioNTech SE (BNTX) from $143 to $128.

BioNTech founders Uğur Şahin and Özlem Türeci are embarking on a new venture, with their original investors and co-founders, Thomas and Andreas Strüngmann, expressing interest in investing again. This move follows their stepping back from BioNTech's leadership, highlighting their continued focus on scientific innovation and entrepreneurship.

Dass sich Ugur Sahin und Özlem Türeci aus dem operativen Geschäft von Biontech zurückziehen, erscheint zunächst seltsam.

BioNTech's stock has fallen sharply after its founders announced their departure, leading investors to question whether to buy the dip.

BioNTech shares experienced a decline following news of its co-founders' plans to exit the company and a financial outlook that missed market forecasts.

BioNTech’s Founding Duo Will Leave to Start New mRNA Firm  Bloomberg.com

BioNTech sues Moderna for patent infringement over COVID shots  Reuters